An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
KORU Medical Systems Appoints Brent Rutland as Vice President of Medical Affairs
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary
KORU Medical Systems (NASDAQ: KRMD) has appointed Brent Rutland as Vice President of Medical Affairs. His role will focus on enhancing the company's clinical and data generation strategies, engaging key opinion leaders, and overseeing the medical affairs team. With 27 years of industry experience, Rutland previously held senior roles at Baxter Healthcare and La Jolla Pharmaceutical, where he facilitated multiple product launches. The leadership change aims to support KORU Medical’s growth by strengthening its medical strategy and clinical evidence generation.
Positive
Brent Rutland brings 27 years of experience, enhancing the company's leadership.
Rutland's expertise in clinical strategies may strengthen KORU Medical's product pipeline.
His experience in launching multiple drugs and devices could positively impact future offerings.
Negative
None.
MAHWAH, N.J.--(BUSINESS WIRE)--
KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use subcutaneous (SQ) infusion solutions, today announced the appointment of Brent Rutland as the Company’s new Vice President of Medical Affairs. Mr. Rutland will provide leadership in the Company’s clinical and data generation strategies, key opinion leader engagement, assessing new subcutaneous drug candidates for use with the Company’s products and overseeing the medical affairs team. Additionally, Mr. Rutland will be the clinical resource for the Company’s efforts in regulatory submissions, failure modes and effects analysis, health hazard evaluations, human factors design, new product development and clinical evaluation updates.
“We are excited to bring Brent’s competence to the organization – his background was a perfect fit. His expertise will advance clinical evidence generation in support of our product pipeline, provide valuable insight to our drug therapy candidates and help develop important key opinion leader relationships,” said Linda Tharby, President and CEO. “Brent has helped build multiple data and clinical strategies, internal teams, and external networks in his past. His deep industry experience and passion for the patient, will make him an impactful contributor to the Company’s strategy.”
Mr. Rutland’s career history spans an impressive 27 years and includes working with Baxter Healthcare as a Senior Medical Science Liaison and most recently with La Jolla Pharmaceutical Company as a Senior Director, Health Outcomes. During his career he helped launch 7 vaccines, 4 drugs and 1 device. Most notably, Brent aided Baxter in the launch of Hylenex for SQ rehydration where he also helped build the Medical Affairs department. He has received several awards throughout his career, with the most recent being the President’s Circle Award for Medical Affairs at La Jolla. Brent holds a Bachelor of Science degree from Texas A&M University, an MBA in Global Management from the University of Houston, and his Master of Public Health from the University of North Carolina in Epidemiology.
“I was immediately drawn to the opportunity to work at KORU Medical as I saw the potential for future growth supported by building out the medical science and the team,” said Brent Rutland, Vice President of Medical Affairs. “Medical affairs helps fulfill the unmet needs of the patient through the generation and delivery of scientific evidence to various key outside stakeholders. I look forward to developing a collaborative strategy to support the Company’s overall goals.”
About KORU Medical
KORU Medical develops, manufactures, and commercializes innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System (the “Freedom System”) currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings. For more information, please visit www.korumedical.com.
Who is Brent Rutland and what is his role at KORU Medical Systems?
Brent Rutland has been appointed as the Vice President of Medical Affairs at KORU Medical Systems, tasked with leading clinical and data generation strategies.
What previous experience does Brent Rutland bring to KORU Medical Systems?
Rutland has 27 years of experience, including senior positions at Baxter Healthcare and La Jolla Pharmaceutical, contributing to multiple product launches.
How might Brent Rutland's appointment impact KORU Medical Systems?
His extensive background in medical affairs and product development is expected to strengthen the company's clinical evidence generation and support its growth.
What products does KORU Medical Systems develop?
KORU Medical develops innovative subcutaneous infusion solutions, including the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers.
